Understanding the interplay of the mixed pathologies of the aging brain - longitudinal multimodal imaging studies

Understanding the interplay of the mixed pathologies of the aging brain - longitudinal multimodal imaging studies - MIZERA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00010532

Enrollment

300

Registered

2016-05-20

Start date

2016-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F01.3 F00.2 I68.0

Interventions

after 36 months, assessment of medical history, neurological/cognitive status, lifestyle variables

after 48 months, assessment of medical history, neurological/cognitive status, lifestyle variables, CSF data, MRI, PET

after 60 months, assessment of medical history, neurological/cognitive status, lifestyle variables

Group 1: Baseline diagnostics in patients with cerebral microbleeds will be conducted as a part of clinical routine, and medical history, neurological and cognitive status, lifestyle variables, data o

after 12 months, assessment of medical history, neurological/cognitive status, lifestyle variables

after 24 months, assessment of medical history, neurological/cognitive status, lifestyle variables, CSF data, MRI, PET

Eligibility

Sex/Gender

All

Age

60 Years to 90 Years

Inclusion criteria

Inclusion criteria: • Microbleeds detectable using MRI (according to STRIVE criteria) • Ages of 60 to 90 years • Agreement to attend the study and to take part in follow-up visits

Exclusion criteria

Exclusion criteria: • Macroinfarctions, intracerebral hemorrhages • Severe stenoses of the extracerebral arteries • Severe vascular risk profile • Severe chronic kidney disease, heart failure • Severe dementia • Cancer (palliative stage) • Neurodegeneration from other diseases (parkinson disease, motor neuron disease, temporal lobe epilepsy, multiple sclerosis, mitochondrial disorders, storage diseases) • Primary psychiatric diseases (schizophrenia, bipolar disorder)

Design outcomes

Primary

Measure	Time frame
We aim to understand, whether cerebral small vessel disease and amyloid depositions act together on certain neurodegeneration patterns, network disturbances, cognitive impairment and dementia development. We will further examine how lifestyle impacts on the interactions between the mixed pathologies of the aging brain. To answer our research questions voxelwise analysis will be conducted using MRI and PET data, and methods of pattern recognition need to be established to quantify microangiopathic lesions. Imaging data will be related to the patients' cognitive state, lifestyle and CSF variables, using distinct statistical models (including e.g. structural equation models and mixed effects linear models) and taking the availability of a longitudinal dataset into account.	—

Measure

Time frame

We aim to understand, whether cerebral small vessel disease and amyloid depositions act together on certain neurodegeneration patterns, network disturbances, cognitive impairment and dementia development. We will further examine how lifestyle impacts on the interactions between the mixed pathologies of the aging brain. To answer our research questions voxelwise analysis will be conducted using MRI and PET data, and methods of pattern recognition need to be established to quantify microangiopathic lesions. Imaging data will be related to the patients' cognitive state, lifestyle and CSF variables, using distinct statistical models (including e.g. structural equation models and mixed effects linear models) and taking the availability of a longitudinal dataset into account.

—

Secondary

Measure	Time frame
We further aim to answer the question, whether there is a relationship between cerebral small vessel disease and cerebral amyloid angiopathy. Again, voxelwise imaging analysis will be conducted taking several follow-up data into account. Imaging data will then be related to the patients' vascular risk factors, cognition and demographics.	—

Countries

Germany

Contacts

Public ContactStefanie Schreiber

Klinik für Neurologie, Otto-von-Guericke Universität Magdeburg, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Standort Magdeburg

stefanie.schreiber@med.ovgu.de0049-391-6713431

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026